{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:35:03Z","timestamp":1788910503461,"version":"build-2803163510"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The International Journal of Biochemistry & Cell Biology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.biocel.2018.11.012","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T12:13:44Z","timestamp":1543580024000},"page":"117-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Ovarian cancer stem cells and their role in drug resistance"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7817-0067","authenticated-orcid":false,"given":"Zalitha","family":"Pieterse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Angelica","family":"Amaya-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Singomat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudra","family":"Binju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bau Dilam","family":"Madjid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4994-2782","authenticated-orcid":false,"given":"Pritinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biocel.2018.11.012_bib0005","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3109\/03008207.2015.1066780","article-title":"Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity","volume":"56","author":"Albini","year":"2015","journal-title":"Connect. Tissue Res."},{"issue":"7","key":"10.1016\/j.biocel.2018.11.012_bib0010","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.biocel.2018.11.012_bib0015","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1158\/1535-7163.MCT-11-0023","article-title":"Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells","volume":"10","author":"Alvero","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.biocel.2018.11.012_bib0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4161\/cc.8.1.7533","article-title":"Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance","volume":"8","author":"Alvero","year":"2009","journal-title":"Cell Cycle (Georgetown, Tex.)"},{"issue":"3","key":"10.1016\/j.biocel.2018.11.012_bib0025","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ygyno.2013.09.034","article-title":"The Wnt\/beta-catenin pathway in ovarian cancer: a review","volume":"131","author":"Arend","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.biocel.2018.11.012_bib0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/onc.2008.374","article-title":"Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells","volume":"28","author":"Baba","year":"2009","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.biocel.2018.11.012_bib0035","first-page":"313","article-title":"Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer","volume":"21","author":"Badiglian Filho","year":"2009","journal-title":"Oncol. Rep."},{"issue":"8","key":"10.1016\/j.biocel.2018.11.012_bib0040","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/0008-5472.CAN-04-3931","article-title":"Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer","volume":"65","author":"Bapat","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biocel.2018.11.012_bib0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/01443615.2017.1336753","article-title":"CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma","volume":"38","author":"Bartakova","year":"2018","journal-title":"J. Obstet. Gynaecol."},{"issue":"1","key":"10.1016\/j.biocel.2018.11.012_bib0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tem.2009.08.005","article-title":"WNT signaling in ovarian follicle biology and tumorigenesis","volume":"21","author":"Boyer","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.biocel.2018.11.012_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.02.002","article-title":"Ovarian cancer stem cell markers: prognostic and therapeutic implications","volume":"322","author":"Burgos-Ojeda","year":"2012","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.biocel.2018.11.012_bib0060","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1158\/1535-7163.MCT-14-0607","article-title":"CD24+ ovarian Cancer cells are enriched for cancer-initiating cells and dependent on JAK2 signaling for growth and metastasis","volume":"14","author":"Burgos-Ojeda","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.biocel.2018.11.012_bib0065","first-page":"564","article-title":"Inhibition of PI3K\/Akt\/mTOR signaling pathway enhances the sensitivity of the SKOV3\/DDP ovarian cancer cell line to cisplatin in vitro","volume":"26","author":"Cai","year":"2014","journal-title":"Chin. J. Cancer Res."},{"issue":"24","key":"10.1016\/j.biocel.2018.11.012_bib0070","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1002\/cncr.26215","article-title":"Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin","volume":"117","author":"Casagrande","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.biocel.2018.11.012_bib0075","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/modpathol.2009.35","article-title":"ALDH1 expression correlates with favorable prognosis in ovarian cancers","volume":"22","author":"Chang","year":"2009","journal-title":"Modern Pathol."},{"issue":"22","key":"10.1016\/j.biocel.2018.11.012_bib0080","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/onc.2012.290","article-title":"c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt\/beta-catenin-ATP-binding cassette G2 signaling","volume":"32","author":"Chau","year":"2013","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.biocel.2018.11.012_bib0085","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1158\/0008-5472.CAN-08-0001","article-title":"Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion","volume":"68","author":"Choi","year":"2008","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biocel.2018.11.012_bib0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2005.01.018","article-title":"Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors","volume":"97","author":"Choi","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biocel.2018.11.012_bib0095","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.2304","article-title":"The cancer stem cell: premises, promises and challenges","volume":"17","author":"Clevers","year":"2011","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.biocel.2018.11.012_bib0100","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/jog.12758","article-title":"Epithelial ovarian cancer with CD117 phenotype is highly aggressive and resistant to chemotherapy","volume":"41","author":"Conic","year":"2015","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"12","key":"10.1016\/j.biocel.2018.11.012_bib0105","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/stem.236","article-title":"CD133 expression defines a tumor initiating cell population in primary human ovarian cancer","volume":"27","author":"Curley","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.biocel.2018.11.012_bib0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.humpath.2016.08.005","article-title":"CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells","volume":"58","author":"Davidson","year":"2016","journal-title":"Hum. Pathol."},{"issue":"34","key":"10.1016\/j.biocel.2018.11.012_bib0115","doi-asserted-by":"crossref","first-page":"55771","DOI":"10.18632\/oncotarget.9908","article-title":"Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer","volume":"7","author":"Deng","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.biocel.2018.11.012_bib0120","doi-asserted-by":"crossref","first-page":"8213","DOI":"10.3390\/ijms14048213","article-title":"The importance of the PI3K\/AKT\/MTOR pathway in the progression of ovarian cancer","volume":"14","author":"Dobbin","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biocel.2018.11.012_bib0125","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biocel.2018.11.012_bib0130","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/0019-509X.154049","article-title":"Advances in tumor markers of ovarian cancer for early diagnosis","volume":"51","author":"Dong","year":"2014","journal-title":"Indian J. Cancer"},{"issue":"12","key":"10.1016\/j.biocel.2018.11.012_bib0135","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1470-2045(08)70308-5","article-title":"The cell of origin of ovarian epithelial tumours","volume":"9","author":"Dubeau","year":"2008","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.biocel.2018.11.012_bib0140","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10456-012-9274-0","article-title":"Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor\/c-kit pathway","volume":"15","author":"Elmasri","year":"2012","journal-title":"Angiogenesis"},{"issue":"3","key":"10.1016\/j.biocel.2018.11.012_bib0145","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1525-1438.2007.01056.x","article-title":"Expression of CD133-1 and CD133-2 in ovarian cancer","volume":"18","author":"Ferrandina","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.biocel.2018.11.012_bib0150","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature11979","article-title":"Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche","volume":"495","author":"Flesken-Nikitin","year":"2013","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.biocel.2018.11.012_bib0155","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/onc.2010.35","article-title":"CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells","volume":"29","author":"Gao","year":"2010","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.biocel.2018.11.012_bib0160","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/onc.2010.35","article-title":"CD24(+) cells from hierarchically organized ovarian cancer are enriched in cancer stem cells","volume":"29","author":"Gao","year":"2010","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.biocel.2018.11.012_bib0165","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1525-1438.2007.01127.x","article-title":"Wnt signaling in ovarian tumorigenesis","volume":"18","author":"Gatcliffe","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.biocel.2018.11.012_bib0170","doi-asserted-by":"crossref","first-page":"128","DOI":"10.33590\/emj\/10312894","article-title":"A theoretical view of ovarian cancer relapse","volume":"2","author":"Giornelli","year":"2017","journal-title":"Eur. Med. J."},{"key":"10.1016\/j.biocel.2018.11.012_bib0175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13048-014-0095-1","article-title":"Notch signaling in serous ovarian cancer","volume":"7","author":"Groeneweg","year":"2014","journal-title":"J. Ovarian Res."},{"issue":"21","key":"10.1016\/j.biocel.2018.11.012_bib0180","first-page":"2896","article-title":"Expression of nestin in ovarian serous cancer and its clinicopathologic significance","volume":"17","author":"He","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.biocel.2018.11.012_bib0185","doi-asserted-by":"crossref","first-page":"e18064","DOI":"10.1371\/journal.pone.0018064","article-title":"Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers","volume":"6","author":"Helland","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biocel.2018.11.012_bib0190","doi-asserted-by":"crossref","first-page":"26788","DOI":"10.1038\/srep26788","article-title":"Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress","volume":"6","author":"Ip","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.biocel.2018.11.012_bib0195","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3748\/wjg.v17.i4.409","article-title":"Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis","volume":"17","author":"Ishiwata","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biocel.2018.11.012_bib0200","doi-asserted-by":"crossref","first-page":"708036","DOI":"10.1155\/2012\/708036","article-title":"Significance of CD44 and CD24 as Cancer stem cell markers: an enduring ambiguity","volume":"2012","author":"Jaggupilli","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.biocel.2018.11.012_bib0205","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.biocel.2016.07.017","article-title":"Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines","volume":"78","author":"Januchowski","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"2","key":"10.1016\/j.biocel.2018.11.012_bib0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12253-012-9574-0","article-title":"Expression patterns of Thymosin beta4 and cancer stem cell marker CD133 in ovarian cancers","volume":"19","author":"Ji","year":"2013","journal-title":"Pathol. Oncol. Res."},{"issue":"3","key":"10.1016\/j.biocel.2018.11.012_bib0215","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cell.2007.04.019","article-title":"Hypoxia Inducible Factors, stem cells and cancer","volume":"129","author":"Keith","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.biocel.2018.11.012_bib0220","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1038\/ncomms9989","article-title":"The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids","volume":"6","author":"Kessler","year":"2015","journal-title":"Nat. Commun."},{"issue":"1a","key":"10.1016\/j.biocel.2018.11.012_bib0225","first-page":"48","article-title":"Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance","volume":"22","author":"Klemba","year":"2018","journal-title":"Contemp. Oncol. (Pozn.)"},{"issue":"8","key":"10.1016\/j.biocel.2018.11.012_bib0230","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.biopha.2014.10.019","article-title":"Colon cancer: cancer stem cells markers, drug resistance and treatment","volume":"68","author":"Kozovska","year":"2014","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.biocel.2018.11.012_bib0235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1023\/B:HIJO.0000032357.16261.c5","article-title":"Tumour Biological Aspects of CD24, A Mucin-Like Adhesion Molecule","volume":"35","author":"Kristiansen","year":"2004","journal-title":"J. Mol. Histol."},{"issue":"1","key":"10.1016\/j.biocel.2018.11.012_bib0240","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ijc.25967","article-title":"Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells","volume":"130","author":"Kryczek","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"7533","key":"10.1016\/j.biocel.2018.11.012_bib0245","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nature14034","article-title":"Blocking PGE(2)-induced tumour repopulation abrogates bladder cancer chemoresistance","volume":"517","author":"Kurtova","year":"2015","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.biocel.2018.11.012_bib0250","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1158\/1535-7163.MCT-10-0563","article-title":"Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer","volume":"9","author":"Landen","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.biocel.2018.11.012_bib0255","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian Cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.biocel.2018.11.012_bib0260","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00418-016-1529-1","article-title":"Thymosin beta4 overexpression regulates neuron production and spatial distribution in the developing avian optic tectum","volume":"147","author":"Lever","year":"2017","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.biocel.2018.11.012_bib0265","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1471-2407-12-201","article-title":"The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells","volume":"12","author":"Liang","year":"2012","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.biocel.2018.11.012_bib0270","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.humpath.2012.12.016","article-title":"Aldehyde dehydrogenase 1\/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma","volume":"44","author":"Liebscher","year":"2013","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.biocel.2018.11.012_bib0275","article-title":"LGR5 promotes epithelial ovarian cancer proliferation, metastasis, and epithelial-mesenchymal transition through the Notch1 signaling pathway","author":"Liu","year":"2018","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.biocel.2018.11.012_bib0280","doi-asserted-by":"crossref","first-page":"e81050","DOI":"10.1371\/journal.pone.0081050","article-title":"Prognostic value of Cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biocel.2018.11.012_bib0285","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.yexmp.2011.06.005","article-title":"Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome","volume":"91","author":"Luo","year":"2011","journal-title":"Exp. Mol. Pathol."},{"issue":"2","key":"10.1016\/j.biocel.2018.11.012_bib0290","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2016.04.038","article-title":"Tumor microenvironment: The culprit for ovarian cancer metastasis?","volume":"377","author":"Luo","year":"2016","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biocel.2018.11.012_bib0295","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12943-017-0638-3","article-title":"Ovarian cancer stem cells: still an elusive entity?","volume":"16","author":"Lupia","year":"2017","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.biocel.2018.11.012_bib0300","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1758834014544121","article-title":"Treatment options in recurrent ovarian cancer: latest evidence and clinical potential","volume":"6","author":"Luvero","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"2","key":"10.1016\/j.biocel.2018.11.012_bib0305","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12015-010-9208-4","article-title":"The role of human aldehyde dehydrogenase in normal and cancer stem cells","volume":"7","author":"Ma","year":"2011","journal-title":"Stem Cell Rev."},{"key":"10.1016\/j.biocel.2018.11.012_bib0310","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2147\/OTT.S101063","article-title":"Prognostic values of aldehyde dehydrogenase 1 isoenzymes in ovarian cancer","volume":"9","author":"Ma","year":"2016","journal-title":"Onco. Ther."},{"issue":"1","key":"10.1016\/j.biocel.2018.11.012_bib0315","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2015.02.003","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in ovarian cancer","volume":"137","author":"Mabuchi","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.biocel.2018.11.012_bib0320","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"43","key":"10.1016\/j.biocel.2018.11.012_bib0325","doi-asserted-by":"crossref","first-page":"E2939","DOI":"10.1073\/pnas.1206400109","article-title":"Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy","volume":"109","author":"McAuliffe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.biocel.2018.11.012_bib0330","first-page":"96","article-title":"The MAPK (ERK) pathway: investigational combinations for the treatment of BRAF-mutated metastatic melanoma","volume":"38","author":"McCain","year":"2013","journal-title":"P T"},{"issue":"4","key":"10.1016\/j.biocel.2018.11.012_bib0335","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4161\/cbt.5.4.2521","article-title":"Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors","volume":"5","author":"McClanahan","year":"2006","journal-title":"Cancer Biol. Ther."},{"issue":"8","key":"10.1016\/j.biocel.2018.11.012_bib0340","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1172\/JCI45273","article-title":"Human ovarian carcinoma\u2013associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production","volume":"121","author":"McLean","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.biocel.2018.11.012_bib0345","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1073\/pnas.1120733109","article-title":"Human ovarian cancer stem\/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance","volume":"109","author":"Meirelles","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biocel.2018.11.012_bib0350","series-title":"Cancer Stem Cells: Methods and Protocols","first-page":"43","article-title":"Evaluation and isolation of cancer stem cells using ALDH activity assay","author":"Mele","year":"2018"},{"issue":"8","key":"10.1016\/j.biocel.2018.11.012_bib0355","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s10585-012-9482-4","article-title":"CD44+\/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival","volume":"29","author":"Meng","year":"2012","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.biocel.2018.11.012_bib0360","series-title":"Ovarian Cancer Metastasis: A Unique Mechanism of Dissemination. Tumor Metastasis","author":"Mitra","year":"2016"},{"issue":"2","key":"10.1016\/j.biocel.2018.11.012_bib0365","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2014.12.005","article-title":"Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species","volume":"137","author":"Mizuno","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"14","key":"10.1016\/j.biocel.2018.11.012_bib0370","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1158\/0008-5472.CAN-07-6341","article-title":"The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects","volume":"68","author":"Moserle","year":"2008","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.biocel.2018.11.012_bib0375","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.3892\/or.2017.5583","article-title":"CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways","volume":"37","author":"Nakamura","year":"2017","journal-title":"Oncol. Rep."},{"issue":"11","key":"10.1016\/j.biocel.2018.11.012_bib0380","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.biocel.2018.11.012_bib0385","first-page":"1168","article-title":"Expression of Nestin and CD133 in serous ovarian carcinoma","volume":"21","author":"Onisim","year":"2016","journal-title":"J. BUON"},{"issue":"7","key":"10.1016\/j.biocel.2018.11.012_bib0390","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ejca.2010.02.024","article-title":"CD44, a therapeutic target for metastasising tumours","volume":"46","author":"Orian-Rousseau","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biocel.2018.11.012_bib0395","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.semcancer.2017.04.009","article-title":"Ovarian cancer stem cells more questions than answers","volume":"44","author":"Ottevanger","year":"2017","journal-title":"Semin. Cancer Biol."},{"issue":"12","key":"10.1016\/j.biocel.2018.11.012_bib0400","doi-asserted-by":"crossref","first-page":"6312","DOI":"10.1158\/0008-5472.CAN-05-3610","article-title":"Notch3 gene amplification in ovarian cancer","volume":"66","author":"Park","year":"2006","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biocel.2018.11.012_bib0405","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2353\/ajpath.2010.100316","article-title":"Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin","volume":"177","author":"Park","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.biocel.2018.11.012_bib0410","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13048-018-0439-3","article-title":"Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors","volume":"11","author":"Parte","year":"2018","journal-title":"J. Ovarian Res."},{"issue":"29","key":"10.1016\/j.biocel.2018.11.012_bib0415","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.biocel.2018.11.012_bib0420","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-13-3456","article-title":"The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation","volume":"74","author":"Raha","year":"2014","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.biocel.2018.11.012_bib0425","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/sj.bjc.6601265","article-title":"Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta","volume":"89","author":"Rask","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.biocel.2018.11.012_bib0430","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/annonc\/mdh139","article-title":"c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study","volume":"15","author":"Raspollini","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biocel.2018.11.012_bib0435","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biocel.2018.11.012_bib0440","first-page":"221","article-title":"ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients","volume":"3","author":"Ricci","year":"2013","journal-title":"Am. J. Cancer Res."},{"issue":"22","key":"10.1016\/j.biocel.2018.11.012_bib0445","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.biocel.2018.11.012_bib0450","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10080241","article-title":"Can stemness and chemoresistance be therapeutically targeted via signaling pathways in ovarian cancer?","volume":"10","author":"Roy","year":"2018","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.biocel.2018.11.012_bib0455","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1089\/hum.2017.168","article-title":"Improved killing of ovarian cancer stem cells by combining a novel chimeric antigen receptor\u2013Based immunotherapy and chemotherapy","volume":"28","author":"R\u00fcdiger","year":"2017","journal-title":"Hum. Gene Ther."},{"issue":"20","key":"10.1016\/j.biocel.2018.11.012_bib0460","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1200\/JCO.2007.14.3420","article-title":"Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study","volume":"26","author":"Schilder","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biocel.2018.11.012_bib0465","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fcell.2017.00018","article-title":"CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells","volume":"5","author":"Senbanjo","year":"2017","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.biocel.2018.11.012_bib0470","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/0008-5472.CAN-06-3958","article-title":"Notch signaling, gamma-secretase inhibitors, and cancer therapy","volume":"67","author":"Shih Ie","year":"2007","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.biocel.2018.11.012_bib0475","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1158\/0008-5472.CAN-10-3175","article-title":"Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival","volume":"71","author":"Silva","year":"2011","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biocel.2018.11.012_bib0480","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2013.05.027","article-title":"Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression","volume":"130","author":"Skubitz","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biocel.2018.11.012_bib0485","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/sj.bjc.6604437","article-title":"CD133\/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers","volume":"99","author":"Smith","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.biocel.2018.11.012_bib0490","first-page":"745","article-title":"Expression of CD133 and CD117 in 64 serous ovarian Cancer cases","volume":"39","author":"Stemberger-Papic","year":"2015","journal-title":"Coll. Antropol."},{"key":"10.1016\/j.biocel.2018.11.012_bib0495","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.canep.2018.05.011","article-title":"Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer","volume":"55","author":"Stewart","year":"2018","journal-title":"Cancer Epidemiol."},{"issue":"4","key":"10.1016\/j.biocel.2018.11.012_bib0500","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"10.1016\/j.biocel.2018.11.012_bib0505","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1080\/14653240902878308","article-title":"Targeting CD24 for treatment of ovarian cancer by short hairpin RNA","volume":"11","author":"Su","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biocel.2018.11.012_bib0510","article-title":"High expressions of Lgr5 and ALDH1 in primary epithelial ovarian Cancer Correlate with advanced tumor stage and grade as well as poor prognosis of the patients","author":"Sun","year":"2015","journal-title":"Gynecol. Obstet. Invest."},{"issue":"2","key":"10.1016\/j.biocel.2018.11.012_bib0515","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ijgc-00009577-200603000-00009","article-title":"Unfavorable prognostic value of CD24 expression in sections from primary and relapsed ovarian cancer tissue","volume":"16","author":"Surowiak","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"30","key":"10.1016\/j.biocel.2018.11.012_bib0520","doi-asserted-by":"crossref","first-page":"11154","DOI":"10.1073\/pnas.0603672103","article-title":"Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness","volume":"103","author":"Szotek","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"16","key":"10.1016\/j.biocel.2018.11.012_bib0525","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.biocel.2018.11.012_bib0530","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1158\/1078-0432.CCR-14-0445","article-title":"Molecular biomarkers of residual disease after surgical debulking of HIGH-GRADE Serous Ovarian Cancer","volume":"20","author":"Tucker","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biocel.2018.11.012_bib0535","doi-asserted-by":"crossref","first-page":"5263974","DOI":"10.1155\/2017\/5263974","article-title":"The crosstalk between ovarian cancer stem cell niche and the tumor microenvironment","volume":"2017","author":"Varas-Godoy","year":"2017","journal-title":"Stem Cells Int."},{"issue":"1","key":"10.1016\/j.biocel.2018.11.012_bib0540","doi-asserted-by":"crossref","first-page":"e29079","DOI":"10.1371\/journal.pone.0029079","article-title":"Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer","volume":"7","author":"Vathipadiekal","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biocel.2018.11.012_bib0545","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semcancer.2014.07.001","article-title":"Cancer stem cells, cancer cell plasticity and radiation therapy","volume":"31","author":"Vlashi","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.biocel.2018.11.012_bib0550","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/onc.2013.537","article-title":"Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer","volume":"34","author":"Xiang","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.biocel.2018.11.012_bib0555","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/labinvest.2014.122","article-title":"Fibroblasts induce expression of FGF4 in ovarian cancer stem-like cells\/cancer-initiating cells and upregulate their tumor initiation capacity","volume":"94","author":"Yasuda","year":"2014","journal-title":"Lab. Investig."},{"issue":"8","key":"10.1016\/j.biocel.2018.11.012_bib0560","doi-asserted-by":"crossref","first-page":"e68187","DOI":"10.1371\/journal.pone.0068187","article-title":"Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population","volume":"8","author":"Yasuda","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biocel.2018.11.012_bib0565","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1155\/2013\/916819","article-title":"Ovarian Cancer stem cells: a new target for Cancer therapy","volume":"2013","author":"Zhan","year":"2013","journal-title":"Biomed Res. Int."},{"issue":"5","key":"10.1016\/j.biocel.2018.11.012_bib0570","doi-asserted-by":"crossref","first-page":"e0196351","DOI":"10.1371\/journal.pone.0196351","article-title":"Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data","volume":"13","author":"Zhang","year":"2018","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.biocel.2018.11.012_bib0575","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.humpath.2013.02.016","article-title":"CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis","volume":"44","author":"Zhang","year":"2013","journal-title":"Hum. Pathol."},{"issue":"11","key":"10.1016\/j.biocel.2018.11.012_bib0580","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","article-title":"Identification and characterization of ovarian cancer-initiating cells from primary human tumors","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biocel.2018.11.012_bib0585","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/modpathol.2011.170","article-title":"CD133 expression associated with poor prognosis in ovarian cancer","volume":"25","author":"Zhang","year":"2012","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.biocel.2018.11.012_bib0590","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1038\/srep05811","article-title":"ROR1 expression correlated with poor clinical outcome in human ovarian cancer","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci. Rep."},{"issue":"48","key":"10.1016\/j.biocel.2018.11.012_bib0595","doi-asserted-by":"crossref","first-page":"17266","DOI":"10.1073\/pnas.1419599111","article-title":"Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["The International Journal of Biochemistry & Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272518302541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272518302541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:13:06Z","timestamp":1761203586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1357272518302541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":119,"alternative-id":["S1357272518302541"],"URL":"https:\/\/doi.org\/10.1016\/j.biocel.2018.11.012","relation":{},"ISSN":["1357-2725"],"issn-type":[{"value":"1357-2725","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ovarian cancer stem cells and their role in drug resistance","name":"articletitle","label":"Article Title"},{"value":"The International Journal of Biochemistry & Cell Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biocel.2018.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}